Therapeutic Area

Type 1 Diabetes

Therapeutic area intelligence for Type 1 Diabetes with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Endocrinology →

TZIELD →

Recent signals(2)

RegulatoryJune 20, 2026

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement

The FDA has granted priority review for the supplemental application of TZIELD (Teplizumab) by Provention Bio.

RegulatoryJune 16, 2026

FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes

The FDA granted accelerated approval for Tzield (teplizumab) to delay insulin production decline in pediatric patients with Stage 3 T1D.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Type 1 Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.